Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus ICE vs placebo plus ICE in relapsed classic Hodgkin lymphoma
CTR20191538Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in classical Hodgkin lymphoma (cHL), sponsored by Innovent Biologics. Started Aug 2019; status: active.
02
Drugs
sintilimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20191538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191538.